Pharmaceutical

ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD patients.

May 20, 2025 - 06:00
ATS 2025: Nucala reduces COPD exacerbations, regardless of severe event history
At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD patients.
Read the original article

Tags:

Previous Article

ATS 2025: Tezepelumab reduces COPD exacerbations in eosinophilic patients, despi...

Next Article

Power of collaboration more pertinent than ever says pharma experts

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

New nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

New nasal spray to reverse fentanyl and other opioid ov...

May 23, 2023

STAT+: Osteoarthritis might be linked to protein known for its role in Alzheimer’s, study says

STAT+: Osteoarthritis might be linked to protein known ...

Jan 24, 2024

Johnson & Johnson reports 6.3% rise in Q2 2023 sales

Johnson & Johnson reports 6.3% rise in Q2 2023 sales

Jul 21, 2023